Results 71 to 80 of about 11,119 (206)

Skin of Color Representation in Hidradenitis Suppurativa Textbooks

open access: yes
JEADV Clinical Practice, EarlyView.
Oswin Chang, Jincheng Shi
wiley   +1 more source

Validated, Reliable, and Novel Skin Frailty Scale for Outpatient Usage and Its Association With Age, Sex, and Non‐Melanoma Skin Cancer: An Observational Study

open access: yesJEADV Clinical Practice, EarlyView.
Skin frailty (SF) is a common condition affecting adults aged ≥65 years. However, the lack of a validated and reliable visual scale to assess SF severity is a barrier to clinical care and research. In this study, we developed a 9‐parameter Skin Frailty Score (SFS), validated by two board‐certified dermatologists and meeting item and scale level content
Po‐Han Ho   +9 more
wiley   +1 more source

Perspektívák a faggyúmirigy kutatásban [PDF]

open access: yes, 2017
L
Dániel Törőcsik   +6 more
core   +1 more source

Correlation between Depression, Quality of Life and Clinical Severity in Patients with Hidradenitis Suppurativa

open access: yesActa Dermato-Venereologica, 2020
Depression is frequent in patients with hidradenitis suppurativa. However, its relationship with quality of life and clinical severity needs further investigation.
Francesca Sampogna   +9 more
doaj   +1 more source

DERMACLEAR: AI‐Powered Insights Into Four Chronic Inflammatory Skin Diseases in Spain

open access: yesJEADV Clinical Practice, EarlyView.
Using an AI‐enhanced analysis of electronic health records from nearly 50,000 patients, the DERMACLEAR study provides real‐world insights into the prevalence, clinical complexity, comorbidities and treatment patterns of HS, CU, PsO and AD in Spain.
Ana Giménez‐Arnau   +11 more
wiley   +1 more source

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange   +4 more
wiley   +1 more source

Pro-inflammatory cytokines in cryptoglandular anal fistulas [PDF]

open access: yes, 2016
Background: Sphincter-preserving procedures for the treatment of transsphincteric fistulas fail in at least one out of every three patients. It has been suggested that failure is due to ongoing disease in the remaining fistula tract.
Gosselink, M.P. (Martijn Pieter)   +5 more
core   +1 more source

1726‐nm Laser Treatment of Hidradenitis Suppurativa Tunnels in a Pediatric Skin of Color Patient: Clinical and Ultrasound Outcomes

open access: yesLasers in Surgery and Medicine, EarlyView.
ABSTRACT Objectives To evaluate the safety, tolerability, and early clinical and ultrasound effects of a 1726‐nm laser for hidradenitis suppurativa (HS) tunnels in a pediatric patient with skin of color. Materials and Methods A 16‐year‐old female (Fitzpatrick skin type VI) with moderate HS and bilateral axillary draining tunnels underwent 4 monthly ...
Emilee M. Dreifus   +4 more
wiley   +1 more source

Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care [PDF]

open access: yes, 2015
Background Boils and abscesses are common in primary care but the burden of recurrent infection is unknown. Aim To investigate the incidence of and risk factors for recurrence of boil or abscess for individuals consulting primary care.
Hayward, AC   +3 more
core   +1 more source

Steatocystoma Multiplex Suppurativa—A Case Report and Review of Treatments

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT We report a case of Steatocystoma Multiplex Suppurativa (SMS), a rare condition that can mimic hidradenitis suppurativa (HS). We also present a review of the surgical and medical therapies, including potential biologic agents.
Justin Tam Vu, Alexis Daniel Lara Rivero
wiley   +1 more source

Home - About - Disclaimer - Privacy